Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples